Barclays analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $29 from $25 and keeps an Overweight rating on the shares. The rally post the Novo Nordisk agreement highlights the incremental market opportunity and removal of the legal overhang for Hims & Hers shares, the analyst tells investors in a research note. Barclays believes the market is still underappreciating Hims’ opportunity from new products.
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
